FRM
CBPO

Fox Run Management’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Fox Run Management’s Portfolio CBPO Stock Details CBPO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,274
Closed -$262K – 853
2018
Q3 		$262K Buy
+3,274
New +$305K 0.11% 393

Other funds holding CBPO

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fox Run Management's CBPO Position: Q4 2018 in Review

Fox Run Management sold out of China Biologic Products Holdings, Inc. (CBPO) in Q4 2018, closing a stake of 3,274 shares — an estimated $262K sold.

Fox Run Management first reported a position in CBPO in Q3 2018 and held it in 1 quarter. The position peaked at $262K in Q3 2018. 67 funds tracked by Wall St. Rank hold CBPO as of Q4 2018.

  • Fox Run Management reported no remaining China Biologic Products Holdings, Inc. position as of Q4 2018 after selling out during the quarter.
  • Fox Run Management sold 3,274 China Biologic Products Holdings, Inc. shares in Q4 2018, an estimated $262K.
  • Fox Run Management first reported a position in China Biologic Products Holdings, Inc. in Q3 2018 and held it in 1 quarter.
  • Fox Run Management's China Biologic Products Holdings, Inc. position peaked at $262K in Q3 2018.
  • 67 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q4 2018.

Based on Fox Run Management's 13F filing for Q4 2018, filed 15 Jan 2019.